Description Results NMA

10% Weight Loss Responders 2.32 [1.94; 2.77]

5% Weight Loss Responders 1.89 [1.71; 2.09]

10% Weight Loss Responders 2.94 [2.41; 3.59]

5% Weight Loss Responders 2.34 [2.09; 2.62]

10% Weight Loss Responders 3.68 [1.94; 7.00]

5% Weight Loss Responders 2.32 [1.68; 3.22]

lorcaserin 10 mg twice daily (n=1603)

vs.

placebo (n=1603)

3 arms trial with lorcaserin 10 mg twice daily, 10 mg once daily, and placebo

double blind

Parallel groups

Sample size: 1603/1603

Primary endpoint: hierarchical testing procedure

FU duration: 1 year

lorcaserin 10mg bid (n=-9)

vs.

placebo (n=-9)

double-blind

Parallel groups

Sample size: -9/-9

Primary endpoint:

FU duration: 52 weeks

lorcaserin 10 mg BID (n=253)

vs.

placebo (n=56)

the lorcaserin 10mg QD was interrupted prematurely due to slow enrollment

double-blind

Parallel groups

Sample size: 253/56

Primary endpoint:

FU duration: 52 weeks